Lord B I, Wright E G
Blood Cells. 1980;6(4):581-93.
Based on earlier findings that haemopoietic tissue contains extractable factors which are capable of specifically inhibiting or stimulating the movement of CFU-S into DNA synthesis, a series of preliminary experiments has now been carried out to investigate their cellular source(s), their activity in vivo, and their applicability to human problems. In vivo treatment of mice, in which femoral CFU-S are proliferating rapidly, with the inhibitory factor reduces the proportion of CFU-S in DNA synthesis to non-significant proportions. In addition, the inhibitor is capable of reducing the number of CFU-S induced to enter S following treatment with hydroxyurea, thus protecting CFU-S from the lethal effects of S-phase cytotoxic agents. Removal of specific types of marrow cells shows that both inhibitor and stimulator are adherent, phagocytic and, in the case of inhibitor, Thy--1-. These results suggest that the producer cells probably reside somewhere in the heterogeneous macrophage complex though their different densities suggest they are probably different cell types. Fresh human bone marrow is found to contain a very similar inhibitor and long-term cultures are also found to produce it continuously. The isolation of the producer cells may thus contribute to the understanding of normal physiological stem cell regulation and, by in vivo application, its eventual manipulation and protection.
基于早期的研究结果,即造血组织含有可提取的因子,这些因子能够特异性地抑制或刺激集落形成单位脾细胞(CFU-S)进入DNA合成阶段,现已开展了一系列初步实验,以研究它们的细胞来源、体内活性及其在人类问题中的适用性。对股骨CFU-S迅速增殖的小鼠进行体内治疗,使用抑制因子可将进入DNA合成阶段的CFU-S比例降低至无显著意义的水平。此外,该抑制剂能够减少在用羟基脲处理后被诱导进入S期的CFU-S数量,从而保护CFU-S免受S期细胞毒性药物的致死作用。去除特定类型的骨髓细胞表明,抑制剂和刺激剂都是黏附性、吞噬性的,就抑制剂而言,它是Thy-1阴性的。这些结果表明,产生细胞可能存在于异质性巨噬细胞复合体的某个部位,尽管它们不同的密度表明它们可能是不同的细胞类型。发现新鲜人骨髓含有一种非常相似的抑制剂,并且长期培养物也被发现能持续产生这种抑制剂。因此,产生细胞的分离可能有助于理解正常的生理干细胞调节,并通过体内应用最终实现对其的操控和保护。